ANRim Biotechnology Co., Ltd., founded in 2023, brings together an interdisciplinary team of experts from nanotechnology and biotechnology. The company is dedicated to developing innovative nanotechnology that can safely, precisely and efficiently access the interior of cells, enabling gene editing and detection. This breakthrough opens new pathways for advanced cell therapy and genetic research. Leveraging strong expertise in nanotechnology and precision medicine, ANRim is committed to advancing next-generation cell therapy and gene editing technologies. Its goal is to provide safer and more affordable medical solutions for patients and to become a pioneering Innovator in the field.
ANRim Biotechnology Company Limited
ANRim Biotechnology Co., Ltd., founded in 2023, brings together an interdisciplinary team of experts from nanotechnology and biotechnology. The company is dedicated to developing innovative nanotechnology that can safely, precisely and efficiently access the interior of cells, enabling gene editing and detection. This breakthrough opens new pathways for advanced cell therapy and genetic research. Leveraging strong expertise in nanotechnology and precision medicine, ANRim is committed to advancing next-generation cell therapy and gene editing technologies. Its goal is to provide safer and more affordable medical solutions for patients and to become a pioneering Innovator in the field.
Team Member(s)
Mr Zhou Ziyuan (PhD, Department of Biomedical Engineering, City University of Hong Kong)
Dr Luo Xuan (Alumna, Department of Biomedical Engineering, City University of Hong Kong)
(Info based on the company's application form)
Achievement(s)
- CityUHK HK Tech 300 Angel Fund (2025)